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Promotion of medical products by
manufacturers to physicians in the US
has been widespread for over a century
[1], and in its traditional form includes
strategies such as direct detailing visits (in-
person product promotion by a pharma-
ceutical representative), sponsorship of
Continuing Medical Education programs,
gifts or other inducements, and free
samples [2]. In the past two decades,
numerous studies have shown that these
interactions shape clinical knowledge and
medication-prescribing behavior in ways
that are not consistent with evidence-
based practices [3,4]. As a result, some
physicians and policymakers have sought
to mitigate their influence. For example,
many hospitals and academic medical
centers have established policies that
require disclosure of certain behaviors that
create conflicts of interest—like service on
a manufacturer’s speaker’s bureau—or
limit excessive non-research consulting
payments that physicians may receive [5–
7]. These local efforts have now been
supplemented in the US by the Centers for
Medicare and Medicaid Services’ Open
Payments program (created by the Physi-
cian Payments Sunshine Act) [8], which
began receiving comprehensive informa-
tion from drug and medical device man-
ufacturers in August 2013 about all
payments made to physicians and hospi-
tals and plans to publicly disseminate the
data starting in 2014.
With greater regulatory attention to
traditional promotional practices, ‘‘non-
traditional’’ forms of promotion remain an
option for pharmaceutical and medical
device companies. Non-traditional promo-
tion can include scientific pursuits or other
business relationships that might appear to
be outside the realm of promotion but that
are conducted for a marketing purpose,
such as seeding trials or funding of patient
advocacy organizations [9,10]. It also
includes targeting promotion to non-phy-
sician health care providers, such as nurse
practitioners, pharmacists, and physician
assistants. With recent changes in health
care financing, these non-physician pro-
viders are taking an increasingly central
role in care delivery, as medicine empha-
sizes interdisciplinary team-based care and
integrative medical homes [11]. Thus,
these providers offer a high-impact mar-
keting alternative to traditional physician-
directed promotion [12].
Grundy and colleagues, in this week’s
issue of PLOS Medicine, provide a system-
atic review of literature addressing the
nature of non-physician providers’ inter-
actions with the medical products industry
[13]. The authors identified fifteen studies
published between 2003 and 2010 that
investigated the type and frequency of
interactions, non-physician providers’ atti-
tudes towards industry interactions, and
the perceived effect of industry influence.
The majority of the studies (11 out of 15)
were conducted in the US, with partici-
pant size ranging from 14 to 1,640. One
conclusion of their review was that nearly
all of the US-based nurse practitioners
responding in the studies have regular
pharmaceutical representative contact
(96%), have received industry-sponsored
meals within the past 6 months (64%),
have attended an educational event during
the past five years paid for by the industry
(96%), and have received free drug
samples (66–86%).
The pervasive contact between non-
physician providers and the medical prod-
ucts industry recalls a survey by Campbell
and colleagues in 2004 that found 94% of
physicians reporting recent interactions
with pharmaceutical industry sales repre-
sentatives [14]. Notably, a follow-up
survey in 2009 found somewhat fewer
physicians (84%) reporting such interac-
tions, while a review of Massachusetts data
from 2011 and 2012 suggests that only
approximately one in four physicians
received high-value monetary gifts (.$50)
[15,16]. Though these are not longitudinal
data, they suggest that recent policy
changes have been successful in insulating
Linked Research Article
This Perspective discusses the fol-
lowing new study published in
PLOS Medicine:
Grundy Q, Bero L, Malone R (2013)
Interactions between non-physician
clinicians and industry: A systematic
review. PLoS Med (10)11: e1001561.
doi:10.1371/journal.pmed.1001561
In a systematic review of studies of
interactions between non-physician
clinicians and industry, Quinn
Grundy and colleagues found that
many of the issues identified for
physicians’ industry interactions ex-
ist for non-physician clinicians.
Citation: Yeh JS, Kesselheim AS (2013) Same Song, Different Audience: Pharmaceutical Promotion Targeting
Non-Physician Health Care Providers. PLoS Med 10(11): e1001560. doi:10.1371/journal.pmed.1001560
Published November 26, 2013
Copyright:  2013 Yeh, Kesselheim. This is an open-access article distributed under the terms of the Creative
Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium,
provided the original author and source are credited.
Funding: Dr. Kesselheim is supported by a Greenwall Faculty Scholarship in Bioethics, a Robert Wood Johnson
Foundation Investigator Award in Health Policy Research, and a career development award from the Agency
for Healthcare Research & Quality (K08HS18465-01).
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: akesselheim@partners.org
Provenance: Commissioned; not externally peer reviewed.
The Perspective section is for experts to discuss the
clinical practice or public health implications of a
published study that is freely available online.
PLOS Medicine | www.plosmedicine.org 1 November 2013 | Volume 10 | Issue 11 | e1001560more physicians from promotional inter-
actions. By contrast, the study from
Grundy and colleagues shows that promo-
tion to non-physician health care provid-
ers remains vibrant.
Current programs intended to provide
some transparency about the prevalence of
pharmaceutical industry marketing may
not reach the non-physician provider
population; most notably, the Open Pay-
ments program only gathers data on
payments provided to physicians, not
nurses, pharmacists, or other non-physi-
cian providers. Though this legislation
could be revised to cover all providers of
health care who are currently omitted
from this federal mandate, we believe it is
unlikely that Congress would be interested
in revisiting the wording of this statute in
the near future. Better regulation should
be taken up at the local level, where
institutional policies should be constructed
to apply to all providers of patient care.
For example, Partners HealthCare, the
enterprise that manages our academic
medical center, has implemented an
industry interaction policy that applies to
all employees [17].
In addition to the pervasiveness of
industry interactions among non-physician
providers, Grundy and colleagues also
highlight parallels in how physicians and
non-physician providers regard these in-
teractions. For example, the review re-
vealed that non-physician providers were
confident that they themselves were im-
mune to marketing influences and that
they were able to detect biases while their
own colleagues were less able to do so.
This cognitive dissonance mirrors similar
results found in physicians and physician
trainees [18]. Grundy and colleagues also
found that study participants generally
have positive attitudes toward such indus-
try interactions and did not support the
need for policies to regulate their behavior.
Thus, the review from Grundy and
colleagues points to the persistent need
for greater education among non-physi-
cian health care providers about how
industry promotion tends to overestimate
the benefits and underemphasize the risks
of products.
Substantial progress has been made in
recent years in raising awareness among
physicians about the conflicts of interest
that can arise in health care delivery and
the effect of marketing on medical prac-
tices. It is time to shine a similar light on
non-traditional forms of promotion, in-
cluding marketing to non-physician pro-
viders.
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